3D MEDICINES (01244): The supplemental application for Envida's conversion from conditional approval to regular approval has been approved by the National Medical Products Administration

date
19:11 18/11/2026
avatar
GMT Eight
3D MEDICINES (01244) announced that the domestic production drug supplemental application for Envida (generic name: Envafolimab Injection) to convert from conditional approval to regular approval was officially approved by the National Medical Products Administration (NMPA) on November 17, 2026, with approval notification number 2026B08210.
3D MEDICINES (01244) announced that the supplemental application for domestic-manufactured drug Envida (generic name: Envafolimab Injection) to convert from conditional approval to regular approval was officially approved by the National Medical Products Administration (NMPA) on November 17, 2026, with approval notification number 2026B08210. Envida (generic name: Envafolimab Injection, original research code: KN035) is a recombinant humanized anti-programmed death ligand 1 (PD-L1) single-domain antibody Fc fusion protein. Envida was independently developed by Alphamab Biopharmaceuticals (Alphamab, an exempted company incorporated under the laws of the Cayman Islands on March 28, 2018 and listed on the Stock Exchange (stock code: 9966), and its subsidiaries (all independent third parties)), and has been co-developed with the Company since 2016. On March 30, 2020, Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (Jiangsu Alphamab, a wholly-owned subsidiary of Alphamab), 3D Medicines and Jiangsu SIMCERE PHARMA Co., Ltd. (Jiangsu Simcere, a subsidiary of SIMCERE PHARMA GROUP LTD., whose shares are listed on the Stock Exchange (stock code: 2096)) entered into a cooperation agreement. Pursuant to the agreement, Jiangsu Simcere was granted the exclusive marketing rights for Envida for oncology indications in mainland China and a right of first refusal for out-licensing or transfer. In January 2024, the Company entered into a license agreement with Alphamab and Glenmark Specialty S.A. (Glenmark), pursuant to which 3D Medicines and Alphamab agreed to grant Glenmark an exclusive license and sublicense for Envida for oncology indications to, among others, develop and commercialize Envida in all fields of oncology use in India, the Asia-Pacific region (excluding Singapore, Thailand and Malaysia), the Middle East and Africa, Russia, CIS countries and Latin America. In addition, as the world's first subcutaneous PD-L1 inhibitor, it was approved by the NMPA in November 2021 for marketing for the treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors.